CSL Share Price Performance
AU$0
-273.72 (-100.00%)
Price AU$0
Fair ValueAU$246.96
Share Pricen/a
CSL Limited Stock Price
- 2 Narratives written by author
- 4 Comments on narratives written by author
- 426 Fair Values set on narratives written by author
CSL Community Narratives
AN
Fair Value AU$246.96 27.6% undervalued intrinsic discount
CSL: Share Price Correction Will Present Opportunity As Vaccine Uncertainty Eases
2users have liked this narrative
0users have commented on this narrative
141users have followed this narrative
RA
Fair Value AU$263.33 32.1% undervalued intrinsic discount
CSL is undervalued in High Tax Scenario
3users have liked this narrative
4users have commented on this narrative
60users have followed this narrative
CSL is undervalued in High Tax Scenario
CSL Limited: Fair Value Assessment Amidst Evolving US Tariff Scenarios Executive Summary This report provides an assessment of the fair value of CSL Limited (CSL) under various potential United States (US) tariff scenarios. CSL, a global biotechnology leader with significant operations in plasma therapies (CSL Behring), influenza vaccines (CSL Seqirus), and iron/nephrology treatments (CSL Vifor), faces potential impacts from evolving US trade policies.Read more
3users have liked this narrative
4users have commented on this narrative
60users have followed this narrative
RA
AU$263.33
32.1% undervalued intrinsic discount
Ramsee Fair Value
Revenue growth
6% p.a.
Profit Margin
18.04%
Future PE
26.33x
Share price in 2030
AU$320.38
CSL: Share Price Correction Will Present Opportunity As Vaccine Uncertainty Eases
Key Takeaways Operational transformation and investment in innovation are expected to drive margin expansion, earnings growth, and faster introduction of high-value therapies. Market expansion, a focused business structure, and strong demand for plasma and specialty products support sustainable top-line growth and premium positioning.Read more
2users have liked this narrative
0users have commented on this narrative
141users have followed this narrative
AN
AU$246.96
27.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
4.21% p.a.
Profit Margin
21.64%
Future PE
25x
Share price in 2028
AU$302.1
Recently Updated Narratives
RA
CSL is undervalued in High Tax Scenario
Fair Value: AU$263.33 32.1% undervalued intrinsic discount
60 followersusers have followed this narrative
4 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CSL: Share Price Correction Will Present Opportunity As Vaccine Uncertainty Eases
Fair Value: AU$246.96 27.6% undervalued intrinsic discount
141 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Very undervalued with excellent balance sheet and pays a dividend.
0 Risks
6 Rewards
CSL Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 09, 2026
- 6.21
- 51.93%
- 19.30%
- 45.9%
About CSL
- Founded
- 1916
- Employees
- 29904
- CEO
- WebsiteView website
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
